1 Min Read
Oct 18 (Reuters) - Cytokinetics Inc :
* Cytokinetics announces first patient enrolled in VIGOR-ALS, an open-label extension clinical trial of tirasemtiv Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.